| Field | Specification |
|---|---|
| CAS no. | |
| Applications | |
| Molecular weight | |
| Molecular formula | C37H35F3N10O9 |
| Purity | |
| SMILES | |
| Form | Solid |
| Storage | |
| Shipping | |
| Catalog no. (Mfr.) | |
| Main SKU |
Compound Overview
Carboxy pyridostatin trifluoroacetate salt is a G-quadruplex ligand with high molecular specificity for RNA over DNA G-quadruplexes. It reduces ATF-5 protein levels, decreases cell proliferation, and hinders stress granule (SG) formation[1][2][3]. It is supplied as an off-white to light yellow solid (C37H35F3N10O9, MW 820.73) at 99.49% purity.
Physical & Chemical Properties
| CAS Number | 2444713-88-4 |
|---|---|
| Molecular Formula | C37H35F3N10O9 |
| Molecular Weight | 820.73 g/mol |
| Purity | 99.49% |
| Appearance | Solid |
| Color | Off-white to light yellow |
| SMILES | O=C(O)CCN1N=NC(COC2=CC(C(NC3=NC4=CC=CC=C4C(OCCN)=C3)=O)=NC(C(NC5=NC6=CC=CC=C6C(OCCN)=C5)=O)=C2)=C1.FC(C(O)=O)(F)F |
| Signaling Pathway | Cell Cycle/DNA Damage |
| Solubility | In Vitro: DMSO: 50 mg/mL (60.92 mM; Requires sonication and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO) |
| Storage | -20°C, sealed storage, away from moisture. In solvent: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). |
| Shipping | Room temperature in continental US; may vary elsewhere. |
Literature Cited
Sources cited in this description and in the In Vitro & In Vivo Data tab. Peer-reviewed publications that used this product are listed under References.
Safety
For Research Use Only. Not for use in diagnostic or therapeutic procedures, and not for human or veterinary use. Handle in accordance with the Safety Data Sheet and your institution's chemical hygiene plan.
In Vitro
| Solvent | Solubility | Notes |
|---|---|---|
| DMSO | 50 mg/mL (60.92 mM) | requires sonication and warming and heat to 60°C; use freshly opened DMSO (absorbed moisture lowers solubility) |
Aliquot the stock solution and store it at -80°C (up to 6 months) or -20°C (up to 1 month); sealed storage, away from moisture; avoid repeated freeze-thaw cycles.
In Vivo
Choose the formulation that suits the animal model and route of administration; percentages are volume ratios of the final working solution. Start from a clear DMSO stock (see In Vitro above), add the co-solvents one at a time in the order listed, mixing after each addition, and prepare the working solution fresh on the day of dosing. If precipitation or phase separation occurs, gentle warming or sonication can help.
Protocol 1
| Composition | 10% DMSO + 40% PEG300 + 5% Tween-80 + 45% saline |
|---|---|
| Result | ≥ 2.5 mg/mL (3.05 mM); clear solution |
| How to prepare | Gives a clear solution at ≥ 2.5 mg/mL (saturation not determined). For 1 mL of working solution: add 100 μL DMSO stock (25.0 mg/mL) to 400 μL PEG300; then 50 μL Tween-80; then 450 μL saline to bring the volume to 1 mL. Saline: dissolve 0.9 g sodium chloride in ddH2O and make up to 100 mL. |
Protocol 2
| Composition | 10% DMSO + 90% (20% SBE-β-CD in saline) |
|---|---|
| Result | ≥ 2.5 mg/mL (3.05 mM); clear solution |
| How to prepare | Gives a clear solution at ≥ 2.5 mg/mL (saturation not determined). For 1 mL of working solution: add 100 μL DMSO stock (25.0 mg/mL) to 900 μL 20% SBE-β-CD in saline. 20% SBE-β-CD in saline: dissolve 2 g SBE-β-CD powder in 10 mL saline until clear (4°C, store up to one week). |
Protocol 3
| Composition | 10% DMSO + 90% Corn Oil |
|---|---|
| Result | ≥ 2.5 mg/mL (3.05 mM); clear solution |
| How to prepare | Gives a clear solution at ≥ 2.5 mg/mL (saturation not determined). Use with caution if continuous dosing will exceed two weeks. For 1 mL of working solution: add 100 μL DMSO stock (25.0 mg/mL) to 900 μL corn oil. |
Data provided by the manufacturer.
In Vitro
Carboxy pyridostatin trifluoroacetate salt (1-25 μM; 3 days) shrinks adult SVZ-derived neurospheres and lowers their cell number, and it blocks proliferation and neurosphere fusion in adult SVZ-derived neurosphere cultures[1]. Stress granule (SG) formation is hindered in U2OS cells by Carboxy pyridostatin trifluoroacetate salt (10 μM; 24 h)[3].
In Vivo
In mice, Carboxy pyridostatin trifluoroacetate salt given at 10 mg/kg (i.p.; every 12 h; 3 injections) significantly lowers the number of PCNA-expressing cells in the adult SVZ, while the number of OLIG2-expressing cells in the corpus callosum rises[1].
| Animal Model | C57BL/6 mice (both sexes, 1-2 months old)[1] |
|---|---|
| Dosage | 10 mg/kg (dissolved in phosphate-buffered saline) |
| Administration | Intraperitoneal injection, every 12 h, 3 injections |
| Result | Reduced the number of PCNA-expressing cells in the adult SVZ of mice, indicating a decrease in cell proliferation. Increased the number of OLIG2-expressing cells in the corpus callosum. Showed no increase in OLIG2-expression in the SVZ. Affected the differentiation of neural stem and progenitor cells in different brain regions. |
Data provided by the manufacturer. Numbered citations refer to the Literature Cited list in the product description.
Need this compound in a format that drops straight into your assay? We can tailor formulation, chemistry, and documentation so your results stay consistent across runs and re-orders.
- Format options: solid or pre-dissolved solution (choose solvent), target concentration, aliquots, light/moisture-protected packaging
- Chemistry options: free base/acid vs salt forms, hydrate/solvate preference, stereoisomer control (single enantiomer or racemate), close analogs
- Add-on labels & handles: D/¹³C/¹⁵N isotopes (LC-MS/internal standards), azide/alkyne or other functional handles for conjugation
- QC & documentation: standard COA or enhanced analytical pack (HPLC/LC-MS/NMR), chiral purity, residual solvents, water content (KF), method-specific specs
- Scale & continuity: mg to gram scale, bulk pricing, lot reservation, repeat-order continuity
To quote quickly, tell us: compound name + CAS/structure (SMILES or mol file), intended assay context, solvent preference, salt/stereochemistry requirements, purity/QC level, and the amount (mg–g).
Can’t find the compound you’re looking for?
Send the CAS or structure and your specs. We can help source it, suggest close equivalents, or discuss custom synthesis with the right QC documentation (RUO).
Guanine quadruplexes in the RNA genome of the tick-borne encephalitis virus: their role as a new antiviral target and in virus biology. Nucleic Acids Res 2022 May 6;50(8):4574-4600. PMID: 35420134
DHX36 is a regulatory switch in the interferon-mediated antiviral response. Sci Adv 2026 May 29;12(22):eaef5520. PMID: 42213826
The effect of G-quadruplexes on TDP43 condensation, distribution, and toxicity. Structure 2025 May 27:S0969-2126(25)00184-4. PMID: 40480222
Transcriptome-wide mapping reveals an RNA-dependent mechanism of platinum cancer drugs. bioRxiv 2025 Dec 23:2025.12.20.694502. PMID: 41509293
bioRxiv. 2024 November 20.
